Norges Bank Takes $8.97 Million Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Norges Bank purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 395,385 shares of the life sciences company's stock, valued at approximately $8,967,000. Norges Bank owned about 0.51% of Integra LifeSciences at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of IART. Nisa Investment Advisors LLC increased its position in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after purchasing an additional 2,800 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Integra LifeSciences by 33.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company's stock valued at $448,000 after buying an additional 4,967 shares in the last quarter. Nordea Investment Management AB grew its holdings in Integra LifeSciences by 4.1% during the fourth quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock worth $2,919,000 after acquiring an additional 5,032 shares during the period. Choreo LLC raised its position in Integra LifeSciences by 29.9% in the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock worth $500,000 after acquiring an additional 5,123 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in Integra LifeSciences in the fourth quarter valued at $180,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IART shares. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Truist Financial lowered their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $22.71.

Integra LifeSciences Trading Down 2.5 %

IART traded down $0.43 during trading on Friday, hitting $16.99. 659,615 shares of the company's stock were exchanged, compared to its average volume of 1,051,657. Integra LifeSciences Holdings Co. has a 1 year low of $15.95 and a 1 year high of $33.04. The stock has a 50 day moving average price of $22.28 and a 200 day moving average price of $22.34. The firm has a market cap of $1.31 billion, a P/E ratio of -188.76, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. During the same period in the prior year, the company earned $0.89 EPS. The firm's revenue was up 11.5% on a year-over-year basis. As a group, analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.